Professor Lencioni ILCA 2011.pdf - Biocompatibles

TAE / TACE versus BSC / suboptimal therapy:meta-analysis of RCTs (2-year survival)Author, journal yearPatientsRandom effects model (DerSimonian and Laird)Odds ratio (95% CI)Lin, Gastroenterology 1988 63GETCH, NEJM 1995 96Bruix, Hepatology 1998 80Pelletier, J Hepatol 1998 73Lo, Hepatology 2002 79Llovet, Lancet 2002 112Overall503Heterogeneity p=0.14Favours treatmentz=–2.3p=0.0170.01 0.1 0.5 1 2 10 100Favours controladapted from Llovet JM, Bruix J. Hepatology 2003;37:429-42